Craft

ProQR Therapeutics

Stock Price

$3.5

2024-10-29

Market Capitalization

$281.8 M

2024-10-29

Revenue

€15.9 M

FY, 2025

ProQR Therapeutics Summary

Company Summary

Overview
ProQR Therapeutics is a company that develops RNA therapies designed for patients suffering from genetic rare diseases. It focuses on conditions that have limited treatment options, including several forms of inherited blindness such as Leber’s congenital amaurosis, Usher syndrome, and autosomal dominant retinitis pigmentosa.
Type
Public
Status
Active
Founded
2012
HQ
Leiden, NL | view all locations
Website
https://www.proqr.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Dinko Valerio

    Dinko Valerio, Co-Founder and Chairman

    • Gerard Platenburg

      Gerard Platenburg, CIO and Co-Founder

      • Alison Lawton

        Alison Lawton, Board Member

        • James Shannon

          James Shannon, Board Member and Advisor

          LocationsView all

          2 locations detected

          • Leiden, ZH HQ

            Netherlands

            Zernikedreef 9

          • Cambridge, MA

            United States

            245 Main St 2nd floor

          ProQR Therapeutics Financials

          Summary Financials

          Revenue (Q1, 2026)
          €2.0M
          Gross profit (Q1, 2026)
          €2.0M
          Net income (Q1, 2026)
          (€13.4M)
          Cash (Q1, 2026)
          €81.1M
          EBIT (Q1, 2026)
          (€13.6M)
          Enterprise value
          $205.7M

          Footer menu